At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Implications for Management of PET Amyloid Classification Technology
In Brief
An observational study evaluating [18F]Flutemetamol for Mild Cognitive Impairment and 2 related conditions. Completed, enrolled 41 participants across 1 site.
Detailed Summary
The main purpose of this study is to explore the impact of an amyloid positron emission tomography and computed tomography (PET/CT) scan on physician diagnosis and management, including drug management and care practices, for patients with a diagnosis of cognitive impairment. This study also intends to capture specific patient-reported outcomes related to patient burden, confidence and satisfaction. The hypothesis is that to aid early diagnosis, individuals with a diagnostically uncertain etiology for their dementia will benefit from knowledge of amyloid plaque burden status, through an alteration of patient diagnosis and management, which will lead to significant changes in patient and care partner reported outcomes.
Study Details
Timeline
Interventions
amyloid PET imaging with \[18F\]Flutemetamol and subsequent modification of diagnosis and management